The European Commission has approved Tevimbra (tislelizumab), alongside gemcitabine and cisplatin, for the first-line treatment of adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. 10 July 2025
BeOne Medicines - the Sino-American oncology specialist formerly known as BeiGene - has announced that the National Institute for Health and Care Excellence (NICE) has recommended Brukinsa (zanubrutinib) to treat relapsed or refractory mantle cell lymphoma (MCL) after one line of treatment. 10 July 2025
Japanese authorities are putting Eisai under pressure to reconsider the price of its Alzheimer’s disease therapy Leqembi (lecanemab), after a government-backed review found that the drug significantly exceeds accepted cost-effectiveness thresholds in the country. 10 July 2025
Shares in Japanese drugmaker Otsuka Holdings closed nearly 2% lower Tuesday, after disappointing clinical trial results from one of its subsidiaries. 8 July 2025
Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero. 7 July 2025
Chinese biotech Brii Biosciences has licensed its experimental antibiotic BRII-693 to domestic pharma business Joincare Group for development and commercialization in China, as part of a technology transfer and exclusive licensing agreement announced on Wednesday. 4 July 2025
A new company is responsible for Japanese promotional activities for Actair, Stallergenes Greer’s sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis. 4 July 2025
Multinational pharmaceutical companies (MNCs) are facing significant challenges in China's vaccine market, as regulatory scrutiny, domestic competition, and changing consumer behaviors disrupt a once-thriving sector. 4 July 2025
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Fruzaqla (fruquintinib) be reimbursed by the National Health Service (NHS), Japanese drug major Takeda’s local subsidiary revealed today. 3 July 2025
The US Food and Drug Administration has granted accelerated approval to sunvozertinib (trade name Zegfrovy) from Dizal (Jiangsu) Pharmaceutical for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 3 July 2025
Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese pharmaceutical company, Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates. 2 July 2025
Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) has been granted approval by the China National Medical Products Administration (NMPA). 30 June 2025
Japanese drugmaker Shionogi has filed a supplemental application in Japan to broaden the use of its oral antiviral Xocova (ensitrelvir), aiming to include children as young as six who weigh at least 20 kilograms. 30 June 2025
Australian biotech Dimerix today revealed it has received the first development milestone payment of 400 million yen (~AU$4.2 million; US$2.7 million) from Japan’ FUSO Pharmaceutical, the exclusive licensee of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 30 June 2025
Cell therapy specialist Candid Therapeutics has entered a strategic collaboration with Shanghai-based EpimAb Biotherapeutics to discover and develop new T-Cell engager (TCE) candidates. 17 December 2024
Japanese drugmaker Kyorin Pharmaceutical has entered into a licensee agreement with Bayer for the novel obstructive sleep apnea (OSA) treatment BAY2925976 and its backup compound discovered by the German pharma major. 17 December 2024
Japan’s largest drugmaker, Takeda Pharmaceuticals, announced it is working with the European Medicines Agency (EMA) to voluntarily withdraw the marketing authorization of Alofisel (darvadstrocel), a treatment for complex perianal fistulas in patients with Crohn’s disease, in the European Union (EU). 16 December 2024
Chinese biotech RemeGen has presented results from a Phase III trial of disitamab vedotin, a HER2-targeted antibody-drug conjugate (ADC), at the San Antonio Breast Cancer Symposium. 16 December 2024
The HSE University BRICS Competition Law and Policy Centre has summarized the first results of its annual analytical study on bringing biologics to the BRICS market. 13 December 2024
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Italy-based CNS specialist Newron Pharmaceuticals has entered into a license agreement with EA Pharma, part of Japan’s Eisai to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated territories. 13 December 2024
Daiichi Sankyo has announced plans to invest 1.1 billion renminbi ($150 million) to build a new manufacturing facility for antibody-drug conjugates (ADCs) in Shanghai's Zhangjiang area. 12 December 2024
Chinese biopharma Hutchmed today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy designation (BTD) for the combination of its Orpathys (savolitinib) and AstraZeneca’s Tagrisso (osimertinib). 12 December 2024
Swiss specialty pharmaceutical company Santhera Pharmaceuticals has received approval from the National Medical Products Administration in China for Agamree (vamorolone). 11 December 2024
South Korean biotech SK Biopharmaceuticals has unveiled the Phase III clinical trial results of Xcopri (cenobamate) in Northeast Asian epilepsy patients through a poster presentation at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, USA. 10 December 2024
The BIOSECURE Act—US legislation aimed at safeguarding the country’s interests against potential security threats from China—is facing further delay. 10 December 2024
China-based biotech Duality Biologic (DualityBio) announced first data from a global Phase I/IIa clinical trial evaluating BNT324/DB-1311, an investigational next-generation antibody-drug conjugate (ADC) targeting the transmembrane glycoprotein B7-H3. 7 December 2024
French ophthalmics specialist Nicox has announced the first commercial sale of Zerviate (cetirizine ophthalmic solution) in China by its exclusive Chinese partner OcuMension Therapeutics.
. 6 December 2024
UK pharma major GSK has into an agreement with Chongqing Zhifei Biological Products (Zhifei) to revize the terms on which Zhifei will commercialize GSK’s shingles vaccine, Shingrix, in mainland China. 5 December 2024
Swedish clinical-stage drug developer Cinclus Pharma, a specialist in treatments for gastric acid-related diseases, had picked up Chinese approval for linaprazan glurate. 5 December 2024
AstraZeneca has brought in Iskra Reic to replace Leon Wang, who is on extended leave from the Anglo-Swedish drugmaker while under investigation in China. 4 December 2024
Shares of US precision medicines firm Relay Therapeutics closed down 6% at $4.39 yesterday after announced a licensing deal for its lirafugratinib. 4 December 2024
A privately-held biotech company developing multiple-dose gene therapies to treat patients with genetic and idiopathic diseases, focusing first on hemophilia B.